Lower HDL-C levels are associated with higher expressions of CD16 on monocyte subsets in coronary atherosclerosis

Xiang, Yu‐Tao; Liang, Bin; Zhang, Xiaokang; Zheng, Fang

doi:10.7150/ijms.47998

Cited by 12 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uncontrolled inflammation with TLR overactivation on CD14 + monocytes has long been recognized as a driving mechanism for atherosclerotic disease ( 115 , 116 ). Population of intermediate monocytes with increased mCD14 and CD16 can independently predict cardiovascular events in patients with coronary artery disease ( 117 , 118 ). CD14 is also known to regulate function of endothelial and smooth muscle cells.…”

Section: Cluster Of Differentiation Cd14—cd14mentioning

confidence: 99%

The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease

Bezhaeva

Karper²,

Quax

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Activation of Toll like receptors (TLR) plays an important role in cardiovascular disease development, progression and outcomes. Complex TLR mediated signaling affects vascular and cardiac function including tissue remodeling and repair. Being central components of both innate and adaptive arms of the immune system, TLRs interact as pattern recognition receptors with a series of exogenous ligands and endogenous molecules or so-called danger associated molecular patterns (DAMPs) that are released upon tissue injury and cellular stress. Besides immune cells, a number of structural cells within the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts and cardiac myocytes express TLRs and are able to release or sense DAMPs. Local activation of TLR-mediated signaling cascade induces cardiovascular tissue repair but in a presence of constant stimuli can overshoot and cause chronic inflammation and tissue damage. TLR accessory molecules are essential in guiding and dampening these responses toward an adequate reaction. Furthermore, accessory molecules assure specific and exclusive TLR-mediated signal transduction for distinct cells and pathways involved in the pathogenesis of cardiovascular diseases. Although much has been learned about TLRs activation in cardiovascular remodeling, the exact role of TLR accessory molecules is not entirely understood. Deeper understanding of the role of TLR accessory molecules in cardiovascular system may open therapeutic avenues aiming at manipulation of inflammatory response in cardiovascular disease. The present review outlines accessory molecules for membrane TLRs that are involved in cardiovascular disease progression. We first summarize the up-to-date knowledge on TLR signaling focusing on membrane TLRs and their ligands that play a key role in cardiovascular system. We then survey the current evidence of the contribution of TLRs accessory molecules in vascular and cardiac remodeling including myocardial infarction, heart failure, stroke, atherosclerosis, vein graft disease and arterio-venous fistula failure.

show abstract

Section: Cluster Of Differentiation Cd14—cd14mentioning

confidence: 99%

The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease

Bezhaeva

Karper²,

Quax

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Three studies examined the association between atherosclerosis and the distribution of monocyte subsets. All three studies reported that the percentage of IM was significantly higher in patients with atherosclerosis compared to healthy controls ( 27 , 46 , 47 ) ( Table 3 ). One study reported a higher percentage of CM ( 46 ), another study reported a lower percentage of CM ( 47 ), and the other study reported no change in the percentage of CM ( 27 ) in patients with atherosclerosis compared to healthy controls ( Table 3 ).…”

Section: Resultsmentioning

confidence: 98%

“…All three studies reported that the percentage of IM was significantly higher in patients with atherosclerosis compared to healthy controls ( 27 , 46 , 47 ) ( Table 3 ). One study reported a higher percentage of CM ( 46 ), another study reported a lower percentage of CM ( 47 ), and the other study reported no change in the percentage of CM ( 27 ) in patients with atherosclerosis compared to healthy controls ( Table 3 ). There was no significant change in the percentage of NCM in subjects with atherosclerosis compared to healthy controls ( 27 , 46 , 47 ) ( Table 3 ).…”

Section: Resultsmentioning

confidence: 98%

The Association Between Monocyte Subsets and Cardiometabolic Disorders/Cardiovascular Disease: A Systematic Review and Meta-Analysis

Rogers

2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Monocyte subsets in humans, i.e., classical (CM), intermediate (IM), and non-classical monocytes (NCM), are thought to differentially contribute to the pathogenesis of atherosclerosis, the leading cause of cardiovascular disease (CVD). However, the association between monocyte subsets and cardiometabolic disorders and CVD is not well-understood. Thus, the aim of the current systematic review and meta-analysis was to evaluate recent findings from clinical studies that examined the association between the distribution of monocyte subsets in subjects with cardiometabolic disorders and CVD compared to healthy controls.Methods: Articles were systematically searched in CINAHL, PubMed and Cochrane Library. Articles were independently screened and selected by two reviewers. Studies that reported the percentage of each monocyte subset were included in the systematic review and meta-analysis. For the meta-analysis, a random-effects model was used to generate pooled standardized mean differences (SMD) between subjects with cardiometabolic disorders and healthy controls.Results: A total of 1,693 articles were screened and 27 studies were selected for qualitative analyses. Among them, six studies were included in the meta-analysis. In total, sample size ranged from 22 to 135 and mean or median age from 22 to 70 years old. We found studies that reported higher percentage and number of IM and/or NCM in subjects with cardiometabolic disorders (9 out of 13 studies) and in subjects with CVD (11 out of 15 studies) compared to healthy controls. In the meta-analysis, the percentage of CM was lower [SMD = −1.21; 95% CI (−1.92, −0.50); P = 0.0009; I2 = 91%] and the percentage of IM [SMD = 0.56; 95% CI (0.23, 0.88); P = 0.0008; I2 = 65%] and NCM [SMD = 1.39; 95% CI (0.59, 2.19); P = 0.0007; I2 = 93%] were higher in subjects with cardiometabolic disorders compared to healthy controls.Conclusions: Individuals with cardiometabolic disorders and CVD may have a higher percentage of IM and NCM than healthy controls. Future studies are needed to evaluate the cause and biological significance of this potential altered distribution of monocyte subsets.

show abstract

“…HDL can impact monocyte development, as it has been shown in murine models that HDL suppresses stem cell proliferation [56,57] and reduces monocytosis [57]. Clinically, there is an inverse correlation between HDL-C level and the level of expression of CD16 on monocytes [58]. The change in CD16 expression would explain the increased proportion of intermediate and nonclassical monocytes in dyslipidemia (Table 3) and in CVD (Table 1) as, by definition, upregulation of CD16 expression would see monocytes no longer classed as 'classical' but deemed to be intermediate (or nonclassical) monocytes [58].…”

Section: Monocyte Count/percentage Changes Relative To Lipidsmentioning

confidence: 99%

Nature versus Number: Monocytes in Cardiovascular Disease

Williams

Mack

et al. 2021

IJMS

View full text Add to dashboard Cite

Monocytes play a key role in cardiovascular disease (CVD) as their influx into the vessel wall is necessary for the development of an atherosclerotic plaque. Monocytes are, however, heterogeneous differentiating from classical monocytes through the intermediate subset to the nonclassical subset. While it is recognized that the percentage of intermediate and nonclassical monocytes are higher in individuals with CVD, accompanying changes in inflammatory markers suggest a functional impact on disease development that goes beyond the increased proportion of these ‘inflammatory’ monocyte subsets. Furthermore, emerging evidence indicates that changes in monocyte proportion and function arise in dyslipidemia, with lipid lowering medication having some effect on reversing these changes. This review explores the nature and number of monocyte subsets in CVD addressing what they are, when they arise, the effect of lipid lowering treatment, and the possible implications for plaque development. Understanding these associations will deepen our understanding of the clinical significance of monocytes in CVD.

show abstract

Lower HDL-C levels are associated with higher expressions of CD16 on monocyte subsets in coronary atherosclerosis

Cited by 12 publications

References 29 publications

The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease

The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease

The Association Between Monocyte Subsets and Cardiometabolic Disorders/Cardiovascular Disease: A Systematic Review and Meta-Analysis

Nature versus Number: Monocytes in Cardiovascular Disease

Contact Info

Product

Resources

About